We have designed a nanoparticle drug delivery system. The system included PLGA, paclitaxel (PTX) and transferrin (TF). This system can specifically target to liver cancer cells through intravenously administration. The PLGA-PTX-TF nanoparticles show excellent liver cancer treatment effect (IC50 4.79 g/mL) and are dose dependent in vitro. The PLGA-PTX-TF nanoparticle also show noticeable anti-tumor efficacy in vivo compared to PLGA-PTX (anti-cancer rate: 79.09% vs. 35.47%). Therefore, PLGA-PTX-TF nanoparticles can be considered as an effective anticancer drug delivery system for liver cancer therapy for the clinical use.
HTML PDFShare this article
Journal of Oncology Medicine & Practice received 142 citations as per Google Scholar report
